Group items tagged

This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications from institutions and organizations that propose to study the effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri-, post-natal development through young adulthood in animal models and humans. Topics of interest pertaining to this PA include, but are not limited to: molecular and cellular mechanisms of cannabis/cannabinoid effects on the developing brain; long term functional consequences of cannabis/cannabinoid exposure on learning and memory, cognitive and emotional development.

This Funding Opportunity Announcement (FOA) encourages exploratory/developmental grant (R21) applications from institutions and organizations that propose to study the effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri-, post-natal development through young adulthood in animal models and humans. Topics of interest pertaining to this PA include, but are not limited to: molecular and cellular mechanisms of cannabis/cannabinoid effects on the developing brain; long term functional consequences of cannabis/cannabinoid exposure on learning and memory, cognitive and emotional development.

Research Grants are offered to encourage the development of new information that contributes to the understanding of the basic etiology and pathogenesis of cystic fibrosis. In addition, consideration will be given to those projects that provide insight into the development of information that may contribute to the development of new therapies for CF. All proposals must be hypothesis driven, and sufficient preliminary data must be provided to justify CFF support. Information derived from such studies will hopefully lead to submission to other funding agencies, such as the National Institutes of Health (NIH).

Research Grants are offered to encourage the development of new information that contributes to the understanding of the basic etiology and pathogenesis of cystic fibrosis. In addition, consideration will be given to those projects that provide insight into the development of information that may contribute to the development of new therapies for CF. All proposals must be hypothesis driven, and sufficient preliminary data must be provided to justify CFF support. Information derived from such studies will hopefully lead to submission to other funding agencies, such as the National Institutes of Health (NIH).

The goal of the Initiative for Maximizing Student Development (IMSD) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. The long-term goal of the program is to enhance the diversity of biomedical research scientists in the Nations workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-intensive institutions (i.e., those with a 3-year average of NIH Research Project Grant funding equal to or above $7.5 million total costs).

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (XXXX).

The overall objective of the LungMAP is to better understand human lung development by building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 1 of the LungMAP has generated foundational data from developing mouse and human lungs, created a web portal for public data sharing, and established a repository of human lung tissues. Phase 2 of the LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung.

The purpose of this project is to develop and implement a virtual bioequivalence trial simulation platform that can be used to perform population-based statistical analysis in complex and computationally intensive physiologically based pharmacokinetic (PBPK) models developed to describe the absorption, distribution and elimination of active pharmaceutical ingredients formulated in complex and non-complex dosage forms administered via oral or non-oral routes. The developed virtual bioequivalence trial simulation platform will be used to generate predictions on the in vivo drug product performance, to perform bioequivalence assessments between brand name and generic drug products and to inform regulatory decisions relating to generic drug development.

The purpose of this project is to develop and implement a virtual bioequivalence trial simulation platform that can be used to perform population-based statistical analysis in complex and computationally intensive physiologically based pharmacokinetic (PBPK) models developed to describe the absorption, distribution and elimination of active pharmaceutical ingredients formulated in complex and non-complex dosage forms administered via oral or non-oral routes. The developed virtual bioequivalence trial simulation platform will be used to generate predictions on the in vivo drug product performance, to perform bioequivalence assessments between brand name and generic drug products and to inform regulatory decisions relating to generic drug development.

The Food and Drug Administration (FDA), Office of Regulatory Affairs (ORA), Office of Training Education and Development (OTED) is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement Grant. The goals of this Cooperative Agreement Grant are to continue the development of the Integrated Food Safety System (IFSS) National Curriculum Standard (NCS) for the laboratory competency and curriculum frameworks, further work on the development and validation of competency statements. As the NCS is completed at each level, then training content can be developed to meet the standard, post web courses and deliver classroom courses to IFSS laboratorians nationwide. Under FSMA Section 209, FDA is directed to improve the training of state, local, territorial and tribal food safety officials and set standards and administer training and education programs to ensure a competent work force doing comparable work.

The purpose of this solicitation is to procure Research & Development services to support the PREVENT Program in the areas of (1) in vivo development/animal efficacy/biomarker development, (2) preclinical product development and CGMP manufacturing of biopharmaceutical agents, and (3) toxicology/pharmacology testing.

The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.

The purpose of the Institutional Research and Academic Career Development Award (IRACDA) Program is to develop a diverse pool of well-trained scientists available to address the nation's biomedical research agenda. The program requires effective partnerships between a research-intensive institution and a teaching-intensive partner institution that has a historical mission or a demonstrated commitment to educating students from groups underrepresented in the biomedical research workforce. The IRACDA program provides support for a mentored postdoctoral research training experience at the research-intensive institution and funding for the IRACDA scholars to develop critical teaching and mentoring skills at a partner institution. The primary goals of the IRACDA program are to develop a diverse pool of well-trained biomedical scientists who have the necessary knowledge and skills to pursue independent academic careers and to enhance science educational offerings at partner institutions. This Funding Opportunity Announcement (FOA) does not allow appointed scholars to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

With this solicitation, NIJ seeks proposals for basic or applied research and development projects. An NIJ forensic science research and development grant supports a discrete, specified, circumscribed project that will: (1) increase the body of knowledge to guide and inform forensic science policy and practice, or (2) lead to the production of useful material(s), device(s), system(s), or method(s) that have the potential for forensic application. The intent of this program is to direct the findings of basic scientific research; research and development in broader scientific fields applicable to forensic science; and ongoing forensic science research toward the development of highly-discriminating, accurate, reliable, cost-effective, and rapid methods for the identification, analysis, and interpretation of physical evidence for criminal justice purposes. Projects should address the challenges and needs of the forensic science community. The operational needs discussed at NIJ's FY 2016 Forensic Science TWG meeting may be found on NIJ.gov. Additional research needs of the forensic science community can be found at the Organization of Scientific Area Committees website. While the goals and deliverables of proposed projects do not necessarily need to result in immediate solutions to the posted challenges or needs, they should speak to them and produce knowledge that adds to work towards eventual resolutions.

This Funding Opportunity Announcement (FOA) encourages applications to develop valid markers to assess the activity of fundamental aging mechanisms in humans that may influence the risk and progression of multiple aging conditions. Projects are encouraged that focus on selected mechanism(s) that may regulate aging changes, assess multiple possible markers for these mechanisms, test methods to improve their measurement properties, characterize their variability among individuals of differing ages and within the same age cohort, and assess their relationships in humans to in vivo functions influenced by the mechanism(s) under study. It is strongly encouraged that each project includes an interdisciplinary research team with expertise, as needed, in the biology of their selected mechanism(s), biomedical aging research, clinical pathology including laboratory assays, imaging methods, human cohort studies, tissue banking, biorepository resources, and statistics. Though the principal focus of the initiative is on development of markers in humans, studies in laboratory animals may also be conducted when necessary for the development of human markers, and potential development of parallel laboratory animal markers of a given mechanism.

USAID is seeking to enhance our malaria vaccine investments through a collaborative design process. The goal of USAID's Malaria Vaccine Development Program (MVDP) is to demonstrate the proof of concept of a vaccine to reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum. Target malaria vaccine end characteristics will include at least 75% efficacy and evidence of affordability. USAID intends to support efforts towards vaccines that have the potential to directly protect recipients against disease caused by P. falciparum such as vaccines that target the pre-erythrocytic (sporozoite and liver stage) and erythrocytic stages of the life cycle. The purpose of this Addendum is to solicit Expressions of Interest (EOI) for novel and innovative approaches to malaria vaccine development that would encompass preclinical development through proof of principle clinical studies to motivate advanced development of a deployable, effective malaria vaccine.

Morton Cure Paralysis Fund (MCPF) is committed to developing effective therapies (cures) for paralysis associated with spinal cord injury and other disorders of the central nervous system (CNS).  MCPF funds activities that hold promise of identifying therapies (cures) for paralysis in humans. MCPF has particular focus of placing projects in the research pipeline that is, enabling scientists to develop the proof concept data necessary to apply for larger NIH grants. MCPF has particular focus of placing projects in the research pipeline that is, enabling scientists to develop the proof concept data necessary to apply for larger NIH grants. The development of effective therapies for chronic injury is a high priority for the organization. Basic research will be supported if it has clear potential to accelerate progress at the applied end of the continuum and/or if it reflects innovative research or a 'change of direction.

The objective of this award is to provide non-salary funds for new and established investigators to research and develop new devices, design and test a significant improvement to an existing technology, develop a new diagnostic, develop a novel research method technology, and/or investigate the application of nanotechnology or methodologies such as computational biology to the field of gastroenterology.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-​effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC&'s current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. APPLY FOR A GRANT Sign up for our newsletter

This program is a continuation of the Plant Genome Research Program (PGRP) that began in FY 1998 as part of the National Plant Genome Initiative (NPGI). Since the inception of the NPGI and the PGRP, there has been a tremendous increase in the availability of functional genomics tools and sequence resources for use in the study of key crop plants and their models. Proposals are welcomed that build on these resources to develop conceptually new and different ideas and strategies to address grand challenge questions in plants of economic importance on a genome-wide scale. There is also a critical need for the development of novel and creative tools to facilitate new experimental approaches or new ways of analyzing genomic data. Especially encouraged are proposals that provide strong and novel training opportunities integral to the research plan and particularly across disciplines that include, but are not limited to, plant physiology, quantitative genetics, biochemistry, bioinformatics and engineering.Activities in four focus areas will be supported in FY 2014: (1) Genomics-empowered plant research to tackle fundamental questions in plant sciences on a genome-wide scale; (2) Development of tools and resources for plant genome research including novel technologies and analysis tools to enable discovery; (3) Mid-Career Investigator Awards in Plant Genome Research (MCA-PGR) to increase participation of investigators trained primarily in fields other than plant genomics; and, (4) Advancing Basic Research in Economically Important Crop Plants (ABR-PG) to develop sequence resources that are critically needed to enable basic research resources in crop plants.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The goal of this NIGMS R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.  To this end, this funding opportunity announcement encourages the development of creative educational activities with a primary focus on Research Experiences and Courses for Skills Development.  Applications are encouraged from research-intensive institutions that propose to develop recent baccalaureate science graduates from diverse backgrounds underrepresented in biomedical and behavioral sciences so that they have the necessary knowledge and skills to pursue PhD or MD-PhD degrees in these fields.  The program provides support for well-designed courses for skills development and extensive research experiences aimed at preparing individuals from diverse backgrounds to complete doctoral degrees.